Viibryd
Viibryd Uses, Dosage, Side Effects, Food Interaction and all others data.
Viibryd is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. Viibryd may also be associated with less sexual dysfunction and weight gain. Viibryd was given FDA approval on January 21, 2011.
Viibryd increases serotonin levels in the brain by inhibiting the reuptake of serotonin while acting as a partial agonist on serotonin-1A receptors. Due to this activity vilazodone has sometimes been referred to as a selective partial agonist and reuptake inhibitor (SPARI).
| Trade Name | Viibryd |
| Availability | Prescription only |
| Generic | Vilazodone |
| Vilazodone Other Names | Vilazodona, Vilazodone, Vilazodonum |
| Related Drugs | Rexulti, sertraline, trazodone, Lexapro, Zoloft, citalopram, Cymbalta, Prozac |
| Weight | 10mg, 20mg, 40mg, |
| Type | Oral kit, oral tablet |
| Formula | C26H27N5O2 |
| Weight | Average: 441.5249 Monoisotopic: 441.216475133 |
| Protein binding | 96-99%. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Canada, United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Viibryd is an antidepressant agent used for the treatment of major depressive disorder that targets the 5-HT transporter and 5-HT1A receptors.
Viibryd is approved for treatment of major depressive disorder.
Viibryd is also used to associated treatment for these conditions: Major Depressive Disorder (MDD)
How Viibryd works
Viibryd selectively inhibits serotonin reuptake in the central nervous system as well as acting as a partial agonist of 5HT-1A receptors. The exact mechanism for how these effects translate to its antidepressant effects are not known, though there is an association between these effects and antidepressive activity.
Toxicity
There is a lack of clinical studies of vilazodone in pregnancy. Animal studies have shown the effects on offspring to be reduced fetal weight, increased mortality, delayed maturation, and decreased fertility in adulthood at doses well above the maximum recommended human dose. Clinical cases of fetal and neonatal exposure to SSRIs and SNRIs have lead to a number of complications including respiratory distress, seizures, and temperature instability. It is not know whether vilazodone is excreted in the breast milk of nursing mothers but animal studies show this is the case for rats. The risk and benefit of breast feeding while taking vilazodone for mother and child must be considered before a decision is made. Safety and effectiveness in pediatric patients has not been established in clinical trials though antidepressants are associated with an increased risk of suicidal thought and behaviour in patients under 24 years. Clinical studies in geriatric patients showed to significant difference in response to vilazodone compared to younger patients. Geriatric patients should be started at a lower dose and titrated to an effective dose as they are more likely to have other comorbidities. Dosage adjustments are not necessary for patients of different genders or with reduced hepatic and renal function.
Food Interaction
- Avoid alcohol.
- Avoid St. John's Wort.
- Take with food.
[Moderate] GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of vilazodone.
Use in combination may result in additive central nervous system depression and
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of vilazodone.
According to the product labeling, vilazodone blood concentrations in the fasted state can be decreased by approximately 50% compared to the fed state, which may result in diminished effectiveness in some patients.
The absolute bioavailability of vilazodone is 72% with food.
In study subjects, administration with food (high-fat or light meal) increased vilazodone peak plasma concentration (Cmax) by approximately 147% to 160% and systemic exposure (AUC) by approximately 64% to 85%.
MANAGEMENT: Patients receiving vilazodone should be advised to avoid consumption of alcohol.
Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how vilazodone affects them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
Viibryd should be taken with food.
Administration without food may result in inadequate drug concentrations and diminished effectiveness.
Viibryd Drug Interaction
Major: amphetamine / dextroamphetamine, amphetamine / dextroamphetamine, duloxetine, escitalopram, lisdexamfetamine, bupropion, bupropion, ondansetron, sertralineModerate: lamotrigineUnknown: aripiprazole, zolpidem, omega-3 polyunsaturated fatty acids, lurasidone, metoprolol, quetiapine, cyanocobalamin, cholecalciferol, alprazolam, cetirizine
Viibryd Disease Interaction
Moderate: depression, angle closure glaucoma, bleeding, hyponatremia, mixed/manic episode, seizure disorder
Volume of Distribution
Viibryd's volume of distribution is unknown but large
Elimination Route
Viibryd's bioavailability is 72% when taken with food.
Half Life
25 hours. Other studies show a half life of 24±5.2h with a single 40mg dose and 28.9±3.2h with repeated doses.
Clearance
Clearance of vilazodone is 19.9-25.1L/h in patients with mild to moderate renal impairment compared to 26.4-26.9L/h in healthy controls.
Elimination Route
1% of the dose is recovered unchanged in the urine and 2% of the dose is recovered unchanged in the feces.
Innovators Monograph
You find simplified version here Viibryd
